**Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant**

Pankaj Mathur,1 Blake Hollowoa,2 Nupur Lala,2 Sharmilan Thanendrarajan,1 Aasiya Matin,1 Atul Kothari,1 Carolina Schinke1

1Myeloma Institute, University of Arkansas Medical Sciences, Medical Center, Little Rock, AR; 2MS4 University of Arkansas Medical Sciences, Little Rock, AR, USA

**Abstract**

Autologous hematopoietic stem cell transplant (AHSCT) is the standard of care in the treatment of multiple myeloma worldwide. Infections are one of the most common complications of the chemotherapy regimen and AHSCT. Thrombotic microangiopathies are one of the rare but potentially life-threatening complications of infections associated with AHSCT. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (HUS) are two most common type of thrombotic microangiopathies. The HUS is classically related to diarrheal illness such as with *E.coli* strain O157: H7 that produce Shiga-like toxins. But it has never been described with *Enterococcus raffinosus* UTI in a multiple myeloma patient after AHSCT.

**Case Report**

The patient is a 62 y.o. Female, with past medical history of hypertension and gastroesophageal reflux disease, was diagnosed with Ig G-lambda multiple myeloma with initial presentation of acute renal insufficiency. Her bone marrow had 60% plasma cells on bone marrow aspirate at the time of diagnosis. She was treated with VDT-ACE (bortezomb, dexamethasone, thalidomide, adriamycin, cyclophosphamide, etoposide) induction chemotherapy and her renal function normalized.

**Introduction**

Autologous hematopoietic stem cell transplant (AHSCT) is the standard of care in the treatment of multiple myeloma worldwide. Infections are commonly associated with the chemotherapy regimen and AHSCT. Thrombotic microangiopathies such as atypical HUS are rare but potentially life-threatening complications of infections associated with AHSCT leading to increased morbidity and mortality after stem cell transplant. Atypical HUS is caused by endothelial toxicity related to chemotherapeutic agents and infections. The complement activation and dysregulation leads to the clinical hallmarks of hemolytic anemia and thrombocytopenia that are also seen in other thrombotic microangiopathies. Plasmapheresis, intravenous immunoglobulins (IVIG) and steroids have been used with variable success. The C5 complement antibody eculizumab, as well as thrombopoietin agonists, are new emerging agents which have been successfully used in some studies. Here we are describing a case of atypical HUS associated with *Enterococcus raffinosus* UTI in a multiple myeloma patient after AHSCT.
dimers were persistently high, and fibrinogen levels continue to be on lower limits of normal. Since atypical HUS has a complement mediated autoimmune pathology, it was decided to give her eculizumab. Meanwhile pending approval of this medication, we decided to give her high dose IVIG (0.5 g/kg × 3 days followed by 1 g/kg × 3 days) in combination with 1 mg/kg prednisone for the underlying autoimmune pathology of the disease. The liver function tests and LDH came down drastically after initiation of IVIG and prednisone, however, her thrombocytopenia and hemolytic anemia persisted. Subsequently, she was started on eculizumab. She received the meningococcal vaccine before starting eculizumab. She received three weekly doses of eculizumab, along with ciprofloxacin prophylaxis. Her hemolytic anemia improved after eculizumab but her thrombocytopenia persisted. The repeat bone marrow examination showed decreased megakaryocytes. She was started on eltrombopag. Her platelets levels stabilized and subsequently discharged home (Figure 2).

**Discussion and Conclusions**

Hemolytic uremic syndrome (HUS) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal injury.\(^1\) The typical HUS primarily affects children.\(^2\) Approximately 90% of cases are preceded by an *Escherichia coli* infection, typically with *E. coli* strain O157:H7 that produce Shiga-like toxins and is thus classified as Shiga toxin-induced HUS (STEC-HUS).\(^1,2\) Typical HUS is generally associated with a good prognosis and low mortality. Atypical HUS also has features of microangiopathic hemolytic anemia, thrombocytopenia, and renal injury. Atypical HUS is associated with increased mortality, and about 50-60% of cases progress to end-stage renal disease.\(^1\) The thrombotic microangiopathies occurring after hematopoietic stem cell transplant are particularly devastating and have very high mortality rates.\(^2,3\)

In our patient, clinical features were suggestive for atypical HUS with *Enterococcus raffinosus* UTI after AHSC. The species *Enterococcus raffinosus* was first recognized in 1989,\(^4\) since then it has been associated with various infections in immunosuppressed patients especially in the acute care hospital settings.\(^4,5\) The natural habitat of *Enterococcus raffinosus* is unknown, but the organism has been found in the oropharyngeal flora of cats. It has been associated with wound infections, abscesses, urinary tract infections, vertebral osteomyelitis and endocarditis.\(^4,5\) However, microangiopathic hemolytic anemia has never been described in the literature with Enterococcus UTI. Though hemolytic uremic syndrome has been described with urinary tract infections with *E. coli*.\(^10,11\) Chiurchiu *et al*.\(^12\) first reported that hemolytic uremic syndrome could be associated with non-diarrheal Shiga toxin producing *Escherichia coli* O157:H7 which causes bacteremia and urinary tract infection. Later, Park *et al*.\(^13\) studied the association between thrombotic microangiopathy and UTI. They found out that 23% of the visits for thrombotic thrombocytopenic purpura had UTI and concluded that occult bacterial infections could cause alterations...
in the coagulation pathways probably resulting from the molecular mimicry between antibodies directed against infectious agents and the ADAMTS13 protein moiety.\textsuperscript{12-14}

Over-activation of the complement system is the most common etiology of atypical HUS.\textsuperscript{14} The dysregulation of alternative complement pathway plays a central role in the pathogenesis of atypical HUS (Figure 3). The regulation of complement pathway is critical in preventing thrombosis from occurring, and genetic mutations have been described in up to 60% of adult aHUS cases.\textsuperscript{14,15} The alteration in the alternative complement pathways especially mutations in complement factor I, complement factor H, and membrane cofactor protein are among the commonly seen abnormalities and account for approximately 50% of aHUS cases.\textsuperscript{14,15} Drugs such as calcineurin inhibitors and sirolimus have also been shown to cause endothelial injury and decrease VEGF expression leading to thrombotic microangiopathy.\textsuperscript{16} Sepsis may cause an alteration in ADAMTS13 activity most likely due to cleavage by circulating proteolytic enzymes.\textsuperscript{17}

Until recently, treatment of aHUS was accomplished with plasma exchange although the efficacy of this treatment was variable and approximately 50% progressed to ESRD.\textsuperscript{18} Eculizumab, a monoclonal anti-C5 component antibody, is a promising new treatment option for aHUS.\textsuperscript{19} Eculizumab has also shown to be useful in treating typical HUS caused by STEC and thrombotic thrombocytopenic purpura (TPP) in which ADAMTS13 levels are below acceptable ranges.\textsuperscript{20,21}

Patients who develop atypical HUS or any thrombotic microangiopathy following AHSC have a high likelihood of succumbing to it and progression to multi-organ failure. This makes it especially important to identify candidates with the underlying genetic anomaly that predisposes them to this condition as well as the patients who will respond to eculizumab. Recently, recombinant human soluble thrombomodulin has also been used successfully to treat thrombotic microangiopathy after hemato poetic stem cell transplantation.\textsuperscript{22} Lastly, we need more studies to determine the exact pathophysiology of all these relatively uncommon disorders which can help proper diagnosis and management of these conditions especially in the setting of autologous stem cell transplants in hematological malignancies.

References

1. Conway EM. HUS and the case for complement. Blood 2015;126:2085-90.
2. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-33
3. Chapin J, Shore T, Forsberg P, et al. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014;12:565-73.
4. Chiurugi VA, Oster SE, Goldberg AA, et al. Ampicillin-resistant Enterococcus raffinosus in an acute-care hospital: case-control study and antimicrobial susceptibilities. J Clin Microbiol 1991;29: 2663-5.
5. Freyaldenhoven BS, Schlieper G, Lütticken R, Reinert RR. Enterococcus raffinosus infection in an immunosuppressed patient: case report and review of the literature. J Infect 2005;51:e121-4.
6. Savini V, Manna A, D’Antonio F, et al. First report of vaginal infection caused by Enterococcus raffinosus. J Med Microbiol 2008;57:672-3.
7. Mastroianni A. Enterococcus raffinosus endocarditis. First case and literature review. Infec Med 2009;17:14-20.
8. Prakash VP, Rao SR, Parija SC. Emergence of unusual species of enterococci causing infections, South India. BMC Infect Dis 2005;5:14.
9. Sandoe JA, Witherdon IR, Settle C. Vertebral osteomyelitis caused by Enterococcus raffinosus. J Clin Microbiol 2001;39:1678-9.
10. Tarr PI, Fouser LS, Stapleton AE, et al. Hemolytic-uremic syndrome in a six-year-old girl after a urinary tract infection with Shiga-toxin-producing Escherichia coli O103:H2. N Engl J Med 1996;335:635-8.
11. Scheutz F, Olesen B, Norgaard A. Two cases of human urinary tract infection complicated by hemolytic uremic syndrome caused by verotoxin-producing Escherichia coli. Clin Infect Dis 2000;31:815-6.
12. Chiurchiu C, Firrincieli A, Santostefano M, et al. Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. Am J Kidney Dis 2003;41:E4.
13. Park YA, Schultz EF, Hay SN, Brecher ME. Thrombotic thrombocytopenic purpura and urinary tract infections: is there a connection? Am J Clin Pathol 2011;135:85-8.
14. Maga TK, Nishimura CJ, Weaver AE, et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010;31:1445.
15. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012;8:622-33.
16. Sartelet H, Toupance O, Lorenzato M, et al. Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. Am J Kidney Dis 2003;41:E4.
17. Schuurman M, Mampena F, D’Hondt I, et al. Vertebral osteomyelitis caused by Enterococcus raffinosus. J Clin Microbiol 2008;57:672-3.
opment of renal failure. Blood 2006;107:528-34.
18. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60.
19. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-81.
20. Lapeyraque AL, Malina M, Frémeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011;364:2561-3.
21. Chapin J, Weksler B, Magro C, Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012;157:772-4.
22. Fujiwara H, Maeda Y, Sando Y, et al. Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Transfusion 2016;56:886-92